RxDoctor Payments Data

Matthew Wright, DO

Internal Medicine · Beaver, PANPI 1770505174

Payments from drug & device makers

$618in general payments, 2019–2025

Across 30 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$126
  • Amgen$90
  • Lilly USA, LLC$79
  • Baxter Healthcare$61
  • Abbott$57
  • Phathom Pharmaceuticals, Inc.$38
  • plus $168 from 8 others

What the payments were for

  • Food & beverage$55790%
  • Other$6110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$618 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$123,167
Medicare patients
232
Services billed
1,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin194$245,902
EliquisApixaban197$200,273
OzempicSemaglutide94$139,217
XareltoRivaroxaban126$121,225
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$69,485
ArexvyRsvpref3 Antigen/As01e/Pf177$56,562
TradjentaLinagliptin44$48,590
Tresiba Flextouch U-100Insulin Degludec21$41,864
JanuviaSitagliptin Phosphate33$38,012
Tresiba Flextouch U-200Insulin Degludec17$30,149
EntrestoSacubitril/Valsartan22$26,391
LinzessLinaclotide24$22,731
Lantus SolostarInsulin Glargine,hum.Rec.Anlog108$21,861
MyrbetriqMirabegron30$21,526
NeurontinGabapentin12$18,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$200,273197 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta, Anoro Ellipta$33$151,113325 claims
Novo NordiskOzempic$126$139,21794 claims
Johnson & JohnsonXarelto$35$121,225126 claims
Astellas Pharma US IncMyrbetriq$17$21,52630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Beaver

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →